Welcome to our dedicated page for Haemonetics Mass news (Ticker: HAE), a resource for investors and traders seeking the latest updates and insights on Haemonetics Mass stock.
Haemonetics Corporation (NYSE: HAE) delivers vital blood and plasma management solutions to healthcare providers worldwide. This page serves as the definitive source for official company announcements, financial updates, and innovation milestones.
Access timely updates on earnings reports, regulatory clearances, and strategic partnerships that shape HAE's leadership in medical technology. Investors will find press releases covering product launches like advanced diagnostic systems, operational expansions, and initiatives enhancing transfusion safety standards.
Our curated news collection helps stakeholders monitor developments across HAE's three core segments: plasma collection technologies, blood center optimization tools, and hospital transfusion management systems. Bookmark this page for direct access to filings, executive commentary, and progress updates on life-saving healthcare solutions.
Haemonetics Corporation (NYSE: HAE) released its financial results for Q2 FY22, ending October 2, 2021. The results are now available on their Investor Relations website. A conference call is scheduled for November 9, 2021, at 8:00 a.m. EST to discuss these results, accessible via a toll-free number and a live webcast. The earnings release and analytical tables have been posted online for investor review. For more details, visit their website.
Haemonetics Corporation (NYSE: HAE) announced the upcoming retirement of CFO William P. Burke, effective June 30, 2022. Burke, who joined the company in 2016, will assist in the transition to his successor. CEO Chris Simon acknowledged Burke's significant contributions to the company’s turnaround and strategic financial initiatives that have fostered long-term growth. Burke expressed his pride in the company's finance team and confidence in Haemonetics' future direction.
Haemonetics Corporation (NYSE: HAE) announced the release date for its second quarter fiscal year 2022 financial results, which is set for 6:00 am EST on November 9, 2021. The company will conduct a conference call at 8:00 am EST on the same day to discuss the results with investors and analysts. Participants can access the call via a toll-free number or an international line, with a conference ID of 3529538. A replay of the call will be available for one year starting November 9, 2021 at 11:00 a.m. EST.
Haemonetics Corporation (NYSE: HAE) announced that its VASCADE MVP® Venous Vascular Closure System is the first and only FDA-approved device for same-day discharge after atrial fibrillation (AF) ablation. This approval follows the successful completion of clinical studies showing that 99.4% to 99.6% of patients were discharged the same day without complications. The VASCADE MVP aims to enhance patient outcomes and care efficiency, which is crucial in the current healthcare landscape accelerated by COVID-19. The company is also poised to enroll patients for further studies in 2022.
Haemonetics Corporation (NYSE: HAE) will present at the Morgan Stanley Virtual Global Healthcare Conference on September 9, 2021, at 8:45 a.m. ET. Chris Simon, the President and CEO, will lead the presentation, which can be accessed live via webcast at Morgan Stanley's website. Haemonetics focuses on innovative medical products that improve patient care and lower healthcare costs, particularly in blood and plasma component collection, surgical suites, and hospital transfusion services. More information can be found on their official website.
Haemonetics Corporation (NYSE: HAE) announced that the financial results for its first quarter of fiscal 2022, ending July 3, 2021, are now available on its Investor Relations website. A conference call is scheduled for August 11, 2021, at 8:00 a.m. ET to discuss these results, with access details provided. The company emphasized its commitment to improving patient care through innovative medical solutions. Further information is accessible via their investor portal.
Haemonetics Corporation (NYSE: HAE) announced Lloyd E. Johnson's election to its Board of Directors and the appointment of Ellen Zane as the new independent Chair. Johnson, a seasoned finance leader with over 35 years of experience, previously held senior roles at Accenture and Delphi Automotive. Zane succeeds Richard Meelia, who retired following the 2021 Annual Meeting. This leadership transition aims to bolster Haemonetics' strategies for enhancing shareholder value.
Haemonetics Corporation (NYSE: HAE) announced it will release its first quarter fiscal year 2022 financial results on August 11, 2021, at 6:00 am EDT. Following this, a conference call will take place at 8:00 am EDT on the same day to discuss the results and answer questions. Investors can access the call via a toll-free number or through an online webcast. A replay will be available for one year starting from August 11, 2021, at 11:00 am EDT.
Haemonetics Corporation (NYSE: HAE) revealed its financial results for the fourth quarter of fiscal 2021, which ended on April 3, 2021. The results can be accessed on the company's Investor Relations website. Following the release, a conference call and webcast will be held on May 13, 2021, at 8:00 a.m. ET, allowing investors to engage with management and learn more about the results. The company’s offerings support healthcare improvements in blood and plasma collection, surgical services, and hospital transfusions. Detailed earnings information is also available through direct links provided in the announcement.
FAQ
What is the current stock price of Haemonetics Mass (HAE)?
What is the market cap of Haemonetics Mass (HAE)?
